Invasive breast carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Invasive breast carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer https://clinicaltrials.eu/trial/a-study-testing-zanidatamab-combined-with-chemotherapy-before-surgery-in-patients-with-her2-positive-breast-cancer/ Wed, 29 Apr 2026 15:08:13 +0000 https://clinicaltrials.eu/trial/a-study-testing-zanidatamab-combined-with-chemotherapy-before-surgery-in-patients-with-her2-positive-breast-cancer/ This study is looking at HER2-positive breast cancer, which is a type of breast cancer where cancer cells have high levels of a protein called HER2. The study will test a medication called zanidatamab, also known as JZP598, given before surgery along with different chemotherapy medicines. The chemotherapy medicines that may be used include paclitaxel, docetaxel, and carboplatin. Some participants will receive zanidatamab with paclitaxel, others will receive zanidatamab with docetaxel and carboplatin, and another group will receive trastuzumab with pertuzumab along with docetaxel and carboplatin. After completing the treatment period, participants may also receive trastuzumab emtansine or paclitaxel albumin-bound. All study medicines are given through a vein as an infusion.

The purpose of this study is to find out how many people in each treatment group have no remaining cancer or only a small amount in the breast and nearby lymph nodes after receiving the study treatment and before having surgery. The study will also look at how safe these treatments are, what side effects they may cause, and how they affect the body. Additionally, the study will examine whether participants are able to have surgery as planned and will follow participants over time to check if the cancer comes back and how long they survive.

Participants in this study will be randomly assigned to one of the treatment groups and will receive the study medicines for several months before having surgery to remove the cancer. During the study, participants will have regular visits where doctors will perform examinations, take blood samples, and do heart tests to check how the treatment is working and monitor for any side effects. Participants will also be asked to complete questionnaires about how they are feeling and any symptoms they may be experiencing. After surgery, participants will continue to be followed to see how well the treatment worked and to monitor their overall health.

]]> Study on Indocyanine Green for Evaluating Surgical Margins in Patients Undergoing Breast-Conserving Surgery for Early Invasive Breast Cancer https://clinicaltrials.eu/trial/study-on-indocyanine-green-for-evaluating-surgical-margins-in-patients-undergoing-breast-conserving-surgery-for-early-invasive-breast-cancer/ Wed, 29 Apr 2026 14:25:40 +0000 https://clinicaltrials.eu/trial/study-on-indocyanine-green-for-evaluating-surgical-margins-in-patients-undergoing-breast-conserving-surgery-for-early-invasive-breast-cancer/ This clinical trial is focused on studying breast cancer, specifically in patients with early-stage invasive breast cancer who are planning to undergo breast-conserving surgery. The study will use a special technique called ICG-fluorescence imaging to help evaluate the surgical margins during the operation. The treatment involves the use of a substance called indocyanine green, which is given as an injection and helps to highlight the areas of interest during surgery.

The purpose of the study is to determine the best strategy for using ICG-fluorescence imaging, including the timing and dose of indocyanine green, to accurately assess the surgical margins. This is important to ensure that all cancerous tissue is removed during surgery. The study will compare the accuracy of this technique at different doses and times, and will also look at how well the breast tumor and nearby lymph nodes show up under the imaging.

Participants in the study will receive the indocyanine green injection, and the imaging will be done during their planned surgery. The study aims to find the most effective way to use this imaging technique to help surgeons make sure they have removed all the cancerous tissue. The trial is expected to continue until 2026, with recruitment starting in December 2023.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>